Semaglutide vs Tirzepatide: What the Evidence Says in 2026
A head-to-head evidence comparison of semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro) — covering mechanisms, weight loss data from STEP and SURMOUNT trials, SURMOUNT-5 head-to-head results, cardiovascular outcomes, and what the evidence actually says about choosing between them.
Both semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro) are FDA-approved for weight management and type 2 diabetes, and both have transformed what’s achievable with medication for obesity. As of 2026, we now have a head-to-head trial comparing them directly — SURMOUNT-5, published in the New England Journal of Medicine — which settles the core efficacy question with high-quality evidence.
This post summarizes what the data actually shows for each drug and where the meaningful differences lie.
Mechanism Differences
The most important difference between these two medications is what receptors they target.
Semaglutide is a selective GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a natural gut hormone released after meals. Semaglutide mimics it, triggering glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and — critically for weight loss — activating satiety pathways in the hypothalamus. GLP-1 receptor agonism is a well-established mechanism with decades of research behind it.
Tirzepatide is a dual GIP/GLP-1 receptor agonist. In addition to GLP-1 agonism, it activates GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP accounts for roughly 60–65% of the natural postprandial incretin response, meaning tirzepatide harnesses more of the body’s existing metabolic signaling. The combined activation appears to produce weight loss effects that exceed GLP-1 agonism alone.
This mechanism difference is the most plausible explanation for tirzepatide’s greater weight loss in trials. It is not just a “stronger” drug — it works on more targets.
Weight Loss: The Numbers
Individual Trial Data
| Trial | Drug | Dose | Duration | Mean Weight Loss |
|---|---|---|---|---|
| STEP 1 | Semaglutide 2.4 mg | Weekly SC | 68 weeks | 14.9% vs 2.4% placebo |
| SURMOUNT-1 | Tirzepatide 15 mg | Weekly SC | 72 weeks | 22.5% vs 2.4% placebo |
STEP 1 (N=1,961) enrolled adults with obesity or overweight with at least one weight-related comorbidity, excluding type 2 diabetes. Semaglutide 2.4 mg achieved 14.9% mean weight loss, with 32% of participants losing 20% or more PMID:33567185.
SURMOUNT-1 (N=2,539) enrolled a similar population and tested tirzepatide at three doses (5 mg, 10 mg, 15 mg). The highest dose achieved 22.5% mean weight loss, with 63% of participants losing 20% or more PMID:35658024. These are different trials with somewhat different populations, so direct comparison requires caution.
SURMOUNT-5: The Head-to-Head Trial
The most important data point for this comparison is SURMOUNT-5, published in the NEJM in 2025. This trial was specifically designed to compare the two drugs head-to-head in the same population under the same conditions.
- Population: ~750 adults with obesity or overweight with weight-related conditions
- Design: Randomized, double-blind, 72 weeks
- Doses: Maximum tolerated doses (tirzepatide up to 15 mg; semaglutide up to 2.4 mg)
Results: Tirzepatide-treated participants lost an average of 20.2% of body weight, versus 13.7% for semaglutide — a difference of 6.5 percentage points favoring tirzepatide. This difference was statistically significant. More tirzepatide participants reached the 10%, 15%, and 20% weight loss thresholds compared to semaglutide SURMOUNT-5, NEJM.
The semaglutide result in SURMOUNT-5 (13.7%) is somewhat lower than STEP 1 (14.9%) — partly a reflection of the different population and comparison context.
What This Means Practically
Tirzepatide produces meaningfully more weight loss than semaglutide at maximum doses. However, individual responses vary substantially. Some people on semaglutide achieve outcomes that match the average tirzepatide result; some on tirzepatide have more modest responses. Population-level data does not predict individual outcomes.
Cardiovascular Outcomes
Semaglutide: Proven CV Benefit
Semaglutide has robust cardiovascular outcomes data from the SELECT trial — a landmark study of over 17,600 adults with obesity and established cardiovascular disease (but without diabetes). SELECT showed semaglutide reduced major adverse cardiovascular events (MACE: CV death, heart attack, stroke) by 20% over an average of ~33 months PMID:37952131.
This led to an additional FDA approval specifically for cardiovascular risk reduction in patients with obesity and cardiovascular disease. Semaglutide has more established CV outcomes data than any other weight loss medication.
Tirzepatide: CV Data Still Emerging
Tirzepatide’s SURMOUNT-MMO trial (a cardiovascular outcomes trial) is ongoing as of 2026. Interim data from SURPASS-CVOT confirmed tirzepatide is non-inferior to dulaglutide for cardiovascular safety in type 2 diabetes, but the definitive cardiovascular outcomes trial in obesity is not yet complete.
Key distinction: Semaglutide has an FDA-approved cardiovascular indication for obesity; tirzepatide does not yet, pending SURMOUNT-MMO results.
Side Effect Profiles
Both drugs share a class effect of gastrointestinal side effects, as GLP-1 receptor agonism slows gastric emptying.
| Side Effect | Semaglutide (STEP 1) | Tirzepatide (SURMOUNT-1) |
|---|---|---|
| Nausea | ~44% | ~33% |
| Diarrhea | ~30% | ~23% |
| Vomiting | ~24% | ~12% |
| Constipation | ~24% | ~24% |
| Discontinuation due to GI AE | ~7% | ~5% |
These rates are from individual trials with different populations, not a direct head-to-head comparison of tolerability. In SURMOUNT-5, GI side effects were numerically higher with tirzepatide but discontinuation rates were similar between groups.
Both drugs carry the same class warnings: thyroid C-cell tumor risk (boxed warning based on rodent data), pancreatitis, gallbladder disease, and contraindication in pregnancy.
Muscle mass loss: Approximately 30% of weight lost with semaglutide in STEP trials is lean mass. Data on tirzepatide suggests similar lean mass effects. Both scenarios make resistance training relevant for those seeking to preserve muscle during weight loss.
The Bottom Line
The evidence picture as of 2026:
- Greater weight loss: Tirzepatide wins on this metric — SURMOUNT-5 showed 20.2% vs 13.7% in the only direct comparison
- Cardiovascular outcomes: Semaglutide has a proven 20% MACE reduction in obese patients with CVD (SELECT); tirzepatide’s outcomes data is pending
- Tolerability: Both are similar; GI side effects are common for both, and individual tolerance varies
- Diabetes indication: Both are approved for type 2 diabetes; tirzepatide showed superior HbA1c reduction in SURPASS-2 vs semaglutide
- Longest track record: Semaglutide (Ozempic approved 2017, Wegovy 2021); tirzepatide is newer (Mounjaro 2022, Zepbound 2023)
For someone with obesity and established cardiovascular disease, semaglutide’s proven CV benefit may be the deciding factor. For someone prioritizing maximum weight loss without CV disease, tirzepatide’s trial data shows a clear advantage.
Neither drug is universally “better” — the right choice depends on individual circumstances, access, cost, tolerability, and clinical priorities.
This article is for educational purposes only. It does not constitute medical advice. Consult a qualified healthcare provider for guidance on medication selection.
See the full evidence dossiers: Semaglutide | Tirzepatide
Sources & Citations
- 1
- 2
- 3
- 4
- 5journalTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)
pmid-34170647
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.